- Home
- CDXS vs CTNM Comparison
CDXS vs CTNM Comparison
Compare CDXS & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CDXS
- CTNM
- Stock Information
- Founded
- CDXS 2002
- CTNM 2009
- Country
- CDXS United States
- CTNM United States
- Employees
- CDXS N/A
- CTNM N/A
- Industry
- CDXS Major Chemicals
- CTNM
- Sector
- CDXS Industrials
- CTNM
- Exchange
- CDXS Nasdaq
- CTNM Nasdaq
- Market Cap
- CDXS 216.6M
- CTNM 248.7M
- IPO Year
- CDXS 2010
- CTNM 2024
- Fundamental
- Price
- CDXS $2.65
- CTNM $11.70
- Analyst Decision
- CDXS Buy
- CTNM Strong Buy
- Analyst Count
- CDXS 2
- CTNM 5
- Target Price
- CDXS $11.00
- CTNM $22.20
- AVG Volume (30 Days)
- CDXS 542.5K
- CTNM 110.4K
- Earning Date
- CDXS 10-30-2025
- CTNM 11-05-2025
- Dividend Yield
- CDXS N/A
- CTNM N/A
- EPS Growth
- CDXS N/A
- CTNM N/A
- EPS
- CDXS N/A
- CTNM N/A
- Revenue
- CDXS $57,164,000.00
- CTNM N/A
- Revenue This Year
- CDXS $12.88
- CTNM N/A
- Revenue Next Year
- CDXS $21.64
- CTNM N/A
- P/E Ratio
- CDXS N/A
- CTNM N/A
- Revenue Growth
- CDXS N/A
- CTNM N/A
- 52 Week Low
- CDXS $1.90
- CTNM $3.35
- 52 Week High
- CDXS $6.08
- CTNM $20.24
- Technical
- Relative Strength Index (RSI)
- CDXS 55.26
- CTNM 53.50
- Support Level
- CDXS $2.46
- CTNM $11.56
- Resistance Level
- CDXS $2.76
- CTNM $12.87
- Average True Range (ATR)
- CDXS 0.16
- CTNM 0.84
- MACD
- CDXS 0.02
- CTNM -0.07
- Stochastic Oscillator
- CDXS 50.97
- CTNM 44.59
About CDXS Codexis Inc.
Codexis Inc is a provider of enzymatic solutions for efficient and scalable therapeutics manufacturing that leverages its proprietary CodeEvolver technology platform to discover, develop, and enhance novel, high-performance enzymes. Codexis enzymes solve challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis' enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. Geographically, it derives maximum revenue from the Americas.
About CTNM Contineum Therapeutics Inc. Class A Common Stock
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.